Evidence map›Paper›PMID 34943412›Full record

ArticleDiagnostics (Basel, Switzerland)2021

Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib.

Takayuki Takeda, Tadaaki Yamada, Keiko Tanimura, Takayuki Nakano, Masaki Ishida, Yusuke Tachibana, Shinsuke Shiotsu, Shigeto Horiuchi, Makoto Hibino, Asuka Okada and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Efficacy and safety of alectinib inTranslational lung cancer research · 2022
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Takayuki TakedaDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8026, Japan.ORCID 0000-0002-8375-6940
Tadaaki YamadaDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.ORCID 0000-0002-6945-281X
Keiko TanimuraDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8026, Japan.ORCID 0000-0002-7826-4466
Takayuki NakanoDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8026, Japan.
Masaki IshidaDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Yusuke TachibanaDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan.
Shinsuke ShiotsuDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan.
Shigeto HoriuchiDepartment of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Fujisawa 251-0041, Japan.
Makoto HibinoDepartment of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Fujisawa 251-0041, Japan.
Asuka OkadaDepartment of Respiratory Medicine, Saiseikai Suita Hospital, Suita 564-0013, Japan.ORCID 0000-0001-5854-2257
Yusuke ChiharaDepartment of Respiratory Medicine, Uji-Tokushukai Medical Center, Uji 611-0041, Japan.
Koichi TakayamaDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.ORCID 0000-0002-7723-8960
Japanese Red Cross Society Kyoto Daini Hospital · JPKyoto Prefectural University of Medicine · JPFujisawa City Hospital · JPKyoto first Red Cross hospital · JPSaiseikai Suita Hospital · JPSuita Tokushukai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognoses of patients with non-small-cell lung cancer (NSCLC) harboring

Indexed as

alectinibanaplastic lymphoma kinase (ALK)non-small-cell lung cancerplatelet-to-lymphocyte ratio (PLR)systemic immune-inflammation index (SII)

Identifiers

PMID34943412
PMCPMC8699991
OpenAlexW3217523413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.